Update on Apealea, Potential Ovarian Cancer Therapy, Set for ASCO 2018 in June

Update on Apealea, Potential Ovarian Cancer Therapy, Set for ASCO 2018 in June
Apealea, a water-soluble formulation of the chemotherapy paclitaxel, is not inferior to the standard formulation, Taxol (cremophor- EL paclitaxel), and may even improve the survival of ovarian cancer patients who responded to platinum-based chemotherapy, updated Phase 3 trial data suggests. The data will be presented June 4 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5 in Chicago, in a poster titled “Nanoparticle micellar formulation of paclitaxel in combination with carboplatin for women with recurrent platinum sensitive ovarian cancer (OAS07-OVA): Overall survival results of a phase 3 randomized trial. The chemotherapeutic agent paclitaxel has a low solubility in water and needs to be coupled with substances that increase its solubility in order to reach cancer cells and exert its effects. Bristol-Myers Squibb has developed Taxol as a combination of paclitaxel and Cremophor EL. But while Cremophor EL is widely used for molecules with low water solubility, the molecule 
Subscribe or to access all post and page content.